Key Takeaways:
Logistics companies are racing to build temperature-controlled infrastructure as GLP-1 weight-loss drugs create a $39 billion cold-chain market.
UPS, FedEx and DHL are pouring billions into temperature-controlled facilities as the surge in GLP-1 weight-loss drugs — now taken by 11 percent of American adults — forces a rapid expansion of pharmaceutical cold-chain capacity.
"The margin for error is small — even a brief stray from the correct temperature can ruin the medicines," said John Bolla, president of healthcare at UPS. "But that's also what's creating such a significant opportunity in healthcare logistics."
UPS announced a $48 million investment in temperature-controlled facilities in June, after posting its first $3 billion healthcare revenue quarter in the three months ended March. DHL plans to invest 2 billion euros ($2.25 billion) in health logistics by 2030, with half allocated to the Americas. FedEx launched a dedicated life sciences organization this month and reported healthcare transportation revenue of nearly $10 billion in fiscal 2026.
The cold-chain logistics market for temperature-sensitive biologics is projected to grow at an 8.3 percent compound annual rate through 2033 to reach roughly $39.1 billion, according to Growth Market Reports. With 1 in 8 Americans now taking GLP-1 medications, according to a July Gallup poll, logistics providers that fail to invest in specialized infrastructure risk losing a fast-growing revenue stream to better-capitalized rivals.
The Covid pandemic put healthcare logistics at center stage in 2020, as shipping temperature-controlled vaccines became crucial to containing the virus. Since then, the pharmaceutical supply chain has only grown more complex. Most injectable GLP-1 medications — including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound — require continuous refrigeration during shipment. The Food and Drug Administration has warned that improper storage can affect medicine quality and recommends patients not use GLP-1 drugs that arrive "warm or with insufficient refrigeration."
Cold Chain Becomes a Competitive Battleground
UPS's healthcare portfolio has gained market share every year since 2021, Chief Executive Officer Carol Tomé told analysts in April. The company is seeing more pharmaceutical companies looking for partners to manage growing volume, Bolla said. "As treatments become more specialized and supply chains become more complex, healthcare companies need partners that can provide not just temperature-controlled storage or transportation, but end-to-end visibility, control and reliability across the entire network."
FedEx is building end-to-end solutions for global pharma customers, said Nick Gennari, the company's president of healthcare. "You have to recognize that there's a patient at the end of every delivery or someone that's waiting to be treated." The company's machine learning engine allows customers to track product movement with predictive capabilities, while its technology identifies healthcare products and treats each differently depending on its needs.
C.H. Robinson surpassed $1 billion in revenue in healthcare logistics over the past year, largely due to GLP-1 drug growth, said Ronnie Davis, the company's vice president of North American surface transportation. "With the rise of GLP-1s and other specialized medicine, it's really creating a competitive nature for the same refrigerated supply resources that are there and, quite candidly, that supply is not unlimited, it's constrained."
DHL uses artificial intelligence to monitor critical life science products, tracking temperatures and anticipating potential issues, said Hendrik Venter, the company's CEO. The logistics firm has launched a pharmaceutical air corridor with dedicated aircraft and a connected network that ensures drugs are not shipped through separate regulatory environments. "You cannot lose a shipment. You cannot replace it. It needs to be delivered on time, every time, in the right quality and temperatures," Venter said.
The GLP-1 boom is reshaping the broader pharmaceutical supply chain. Drugmakers are racing to develop oral formulations with longer shelf lives, which could reduce cold-chain requirements over time. For now, the refrigerated capacity race is just beginning, and the companies that build the most reliable networks stand to capture a disproportionate share of a market projected to nearly double in less than a decade.
This article is for informational purposes only and does not constitute investment advice.
